Biofrontera submits study report of pharmacokinetics study to FDA
February 24, 2021 08:30 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the...
Biofrontera AG: Ludwig Lutter appointed new Chief Financial Officer effective March 1, 2021
February 02, 2021 10:35 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary revenue figures for the full year 2020
January 08, 2021 09:35 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds
November 12, 2020 04:27 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00%...
Biofrontera reports third quarter and first nine months 2020 results
November 11, 2020 07:00 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its...
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
October 14, 2020 04:30 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
October 08, 2020 11:04 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court
September 22, 2020 12:02 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in...
Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021
August 20, 2020 13:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified...
Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
August 13, 2020 16:50 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated...